Hospital Mater Dei (MATD3) Q3 2025 earnings summary

Executive summary

• Achieved record net revenue and EBITDA in 3Q25 and 9M25, with operational cash generation at its highest level and net debt reduction both year-over-year and quarter-over-quarter.

• Notable growth in oncology patients and surgical procedures, with standout performance in RMBH, Nova Lima, Salvador, and Uberlândia units.

• Recognition for hospital quality and patient satisfaction, including highest network-wide NPS and QGA seal for data reliability.

• Major advancements in robotic-assisted surgeries and CAR-T cell therapy for onco-hematological treatment.

Financial highlights

• Net revenue reached BRL 568 million in 3Q25, up 16.3% YoY and 4.0% QoQ; average ticket per bed increased by 10.9% YoY.

• Adjusted EBITDA rose to BRL 126 million, up 38.7% YoY and 9.3% QoQ, with margin improving to 22.2%.

• Net income for 3Q25 was BRL 27.5 million, up 10.1% YoY and 1.4% QoQ; adjusted for debenture settlement, net income would be BRL 35 million.

• Gross margin improved to 30.1% in 3Q25, up 1.4pp YoY.

• Operating cash flow in 3Q25 was BRL 134 million, with cash and equivalents at BRL 680 million at quarter-end.

Outlook and guidance

• Continued focus on operational efficiency, cost control, and revenue growth through specialty mix and price adjustments.

• Ongoing investments in advanced therapies, robotic surgery, and technology to drive future growth.

• Management expects further improvements in occupancy and patient mix to sustain revenue and margin growth.